BriaCell Therapeutics Joins MSK's 2025 Therapeutics Accelerator Program
PorAinvest
jueves, 14 de agosto de 2025, 8:35 pm ET1 min de lectura
BCTX--
As one of the world’s foremost cancer research and treatment institutions, MSK offers over 135 years of leadership in patient care, education, and discovery. The MSK Therapeutics Accelerator Cohort program provides BriaCell with access to MSK’s expertise and institutional resources, including Good Manufacturing Practice (GMP) manufacturing services, Investigational New Drug (IND) Application preparation and submission, and regulatory strategy support.
“We are honored to work with the scientific and clinical experts at MSK Therapeutics Accelerator,” stated Dr. William V. Williams, BriaCell’s President and CEO. “MSK’s deep expertise in cancer therapy development and state-of-the-art resources make it an ideal partner to accelerate our personalized off-the-shelf immunotherapy platform.”
Eileen Flowers, PhD, Director of Technology Development & Licensing in the Office of Entrepreneurship and Commercialization at MSK, added, “We are excited to welcome BriaCell into the cohort program.”
Dr. Miguel Lopez-Lago, BriaCell’s Chief Scientific Officer, expressed optimism about the potential of Bria-OTS+ to transform cancer care, stating, “Our participation in this cohort program is yet another step towards achieving that vision.”
BriaCell Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies to transform cancer care. The company’s latest financial position and technical indicators present challenges, but recent corporate developments, including this collaboration with MSK, offer potential upside.
References:
[1] https://www.biospace.com/press-releases/briacell-selected-for-msks-2025-therapeutics-accelerator-program-for-bria-ots-for-cancer
[2] https://drug-dev.com/briacell-selected-for-msks-2025-therapeutics-accelerator-program-for-bria-ots-for-cancer/
BriaCell Therapeutics has been selected for Memorial Sloan Kettering Cancer Center's 2025 Therapeutics Accelerator Program to advance Bria-OTS+ immunotherapy development. The collaboration aims to accelerate development and regulatory processes for the cancer treatment. Despite a challenging financial position and mixed technical indicators, recent corporate developments provide potential upside.
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ; TSX: BCT) has been selected for Memorial Sloan Kettering Cancer Center’s (MSK) 2025 Therapeutics Accelerator Program, aiming to accelerate the clinical development of Bria-OTS+, the company’s next-generation personalized off-the-shelf immunotherapy. This collaboration is intended to expedite Bria-OTS+ development for multiple cancer indications, including metastatic breast cancer and prostate cancer.As one of the world’s foremost cancer research and treatment institutions, MSK offers over 135 years of leadership in patient care, education, and discovery. The MSK Therapeutics Accelerator Cohort program provides BriaCell with access to MSK’s expertise and institutional resources, including Good Manufacturing Practice (GMP) manufacturing services, Investigational New Drug (IND) Application preparation and submission, and regulatory strategy support.
“We are honored to work with the scientific and clinical experts at MSK Therapeutics Accelerator,” stated Dr. William V. Williams, BriaCell’s President and CEO. “MSK’s deep expertise in cancer therapy development and state-of-the-art resources make it an ideal partner to accelerate our personalized off-the-shelf immunotherapy platform.”
Eileen Flowers, PhD, Director of Technology Development & Licensing in the Office of Entrepreneurship and Commercialization at MSK, added, “We are excited to welcome BriaCell into the cohort program.”
Dr. Miguel Lopez-Lago, BriaCell’s Chief Scientific Officer, expressed optimism about the potential of Bria-OTS+ to transform cancer care, stating, “Our participation in this cohort program is yet another step towards achieving that vision.”
BriaCell Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies to transform cancer care. The company’s latest financial position and technical indicators present challenges, but recent corporate developments, including this collaboration with MSK, offer potential upside.
References:
[1] https://www.biospace.com/press-releases/briacell-selected-for-msks-2025-therapeutics-accelerator-program-for-bria-ots-for-cancer
[2] https://drug-dev.com/briacell-selected-for-msks-2025-therapeutics-accelerator-program-for-bria-ots-for-cancer/
Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema
Comentarios
Aún no hay comentarios